ValuEngine upgraded shares of Sensus Healthcare (NASDAQ:SRTS) from a hold rating to a buy rating in a research report report published on Saturday, ValuEngine reports.

SRTS has been the topic of a number of other reports. HC Wainwright reissued a buy rating and set a $9.00 target price on shares of Sensus Healthcare in a research report on Monday, May 13th. TheStreet downgraded Sensus Healthcare from a c- rating to a d+ rating in a research report on Wednesday, May 22nd. Alliance Global Partners downgraded Sensus Healthcare from a buy rating to a neutral rating in a research report on Friday, May 10th. Finally, Maxim Group restated a buy rating and set a $11.00 price target on shares of Sensus Healthcare in a research note on Friday, May 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $9.50.

SRTS stock opened at $6.01 on Friday. Sensus Healthcare has a twelve month low of $4.75 and a twelve month high of $9.23. The firm has a market capitalization of $98.09 million, a P/E ratio of -42.93 and a beta of -0.21. The business’s 50-day moving average price is $5.35.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, August 8th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. Sensus Healthcare had a negative return on equity of 8.89% and a negative net margin of 8.65%. The business had revenue of $7.48 million for the quarter, compared to the consensus estimate of $8.04 million. Equities analysts predict that Sensus Healthcare will post -0.13 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in Sensus Healthcare by 10.2% during the fourth quarter. BlackRock Inc. now owns 26,031 shares of the company’s stock worth $192,000 after purchasing an additional 2,418 shares during the period. Wells Fargo & Company MN bought a new position in Sensus Healthcare during the second quarter worth about $30,000. Northern Trust Corp bought a new position in Sensus Healthcare during the fourth quarter worth about $86,000. BerganKDV Wealth Management LLC bought a new position in Sensus Healthcare during the first quarter worth about $88,000. Finally, B. Riley Wealth Management Inc. bought a new position in Sensus Healthcare during the first quarter worth about $117,000. Hedge funds and other institutional investors own 9.53% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

See Also: Cash Flow Analysis in Stock Selection

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.